150 related articles for article (PubMed ID: 17440835)
1. Reduced survivin expression and tumor cell survival during chronic hypoxia and further cytotoxic enhancement by the cyclooxygenase-2 inhibitor celecoxib.
Kardosh A; Soriano N; Pyrko P; Liu YT; Jabbour M; Hofman FM; Schönthal AH
J Biomed Sci; 2007 Sep; 14(5):647-62. PubMed ID: 17440835
[TBL] [Abstract][Full Text] [Related]
2. Celecoxib inhibits the expression of survivin via the suppression of promoter activity in human colon cancer cells.
Sakoguchi-Okada N; Takahashi-Yanaga F; Fukada K; Shiraishi F; Taba Y; Miwa Y; Morimoto S; Iida M; Sasaguri T
Biochem Pharmacol; 2007 May; 73(9):1318-29. PubMed ID: 17270149
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo.
Pyrko P; Soriano N; Kardosh A; Liu YT; Uddin J; Petasis NA; Hofman FM; Chen CS; Chen TC; Schönthal AH
Mol Cancer; 2006 May; 5():19. PubMed ID: 16707021
[TBL] [Abstract][Full Text] [Related]
4. Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via down-regulation of PI3K/Akt.
Liu B; Shi ZL; Feng J; Tao HM
Cell Biol Int; 2008 May; 32(5):494-501. PubMed ID: 18078766
[TBL] [Abstract][Full Text] [Related]
5. Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib.
Kardosh A; Golden EB; Pyrko P; Uddin J; Hofman FM; Chen TC; Louie SG; Petasis NA; Schönthal AH
Cancer Res; 2008 Feb; 68(3):843-51. PubMed ID: 18245486
[TBL] [Abstract][Full Text] [Related]
6. TRAIL-mediated apoptosis in malignant glioma cells is augmented by celecoxib through proteasomal degradation of survivin.
Gaiser T; Becker MR; Habel A; Reuss DE; Ehemann V; Rami A; Siegelin MD
Neurosci Lett; 2008 Sep; 442(2):109-13. PubMed ID: 18634847
[TBL] [Abstract][Full Text] [Related]
7. The anti-proliferative potency of celecoxib is not a class effect of coxibs.
Schiffmann S; Maier TJ; Wobst I; Janssen A; Corban-Wilhelm H; Angioni C; Geisslinger G; Grösch S
Biochem Pharmacol; 2008 Jul; 76(2):179-87. PubMed ID: 18547544
[TBL] [Abstract][Full Text] [Related]
8. The cyclooxygenase-2 selective inhibitor celecoxib suppresses proliferation and invasiveness in the human oral squamous carcinoma.
Kwak YE; Jeon NK; Kim J; Lee EJ
Ann N Y Acad Sci; 2007 Jan; 1095():99-112. PubMed ID: 17404023
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis.
Kang KB; Wang TT; Woon CT; Cheah ES; Moore XL; Zhu C; Wong MC
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):888-96. PubMed ID: 17293239
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of growth inhibitory effects of cyclooxygenase-2 inhibitor-NS398 on cancer cells.
Li S; Tong Q; Zhang W; Wang Q; Chen Z; Wu Q
Cancer Invest; 2008 May; 26(4):333-7. PubMed ID: 18443952
[TBL] [Abstract][Full Text] [Related]
11. Celecoxib induces apoptosis by inhibiting the expression of survivin in HeLa cells.
Fukada K; Takahashi-Yanaga F; Sakoguchi-Okada N; Shiraishi F; Miwa Y; Morimoto S; Sasaguri T
Biochem Biophys Res Commun; 2007 Jun; 357(4):1166-71. PubMed ID: 17466271
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of photodynamic therapy by 2,5-dimethyl celecoxib, a non-cyclooxygenase-2 inhibitor analog of celecoxib.
Ferrario A; Lim S; Xu F; Luna M; Gaffney KJ; Petasis NA; Schönthal AH; Gomer CJ
Cancer Lett; 2011 May; 304(1):33-40. PubMed ID: 21339042
[TBL] [Abstract][Full Text] [Related]
13. Survivin is a downstream target and effector of sulindac-sensitive oncogenic Stat3 signalling in head and neck cancer.
Scheper MA; Nikitakis NG; Sauk JJ
Int J Oral Maxillofac Surg; 2007 Jul; 36(7):632-9. PubMed ID: 17566705
[TBL] [Abstract][Full Text] [Related]
14. Celecoxib antagonizes the cytotoxicity of cisplatin in human esophageal squamous cell carcinoma cells by reducing intracellular cisplatin accumulation.
Yu L; Chen M; Li Z; Wen J; Fu J; Guo D; Jiang Y; Wu S; Cho CH; Liu S
Mol Pharmacol; 2011 Mar; 79(3):608-17. PubMed ID: 21177414
[TBL] [Abstract][Full Text] [Related]
15. CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells.
Chen S; Liu X; Yue P; Schönthal AH; Khuri FR; Sun SY
Mol Pharmacol; 2007 Nov; 72(5):1269-79. PubMed ID: 17684158
[TBL] [Abstract][Full Text] [Related]
16. The effects of knockdown of wild-type survivin, survivin-2B or survivin-delta3 on the radiosensitization in a soft tissue sarcoma cells in vitro under different oxygen conditions.
Kappler M; Rot S; Taubert H; Greither T; Bartel F; Dellas K; Hänsgen G; Trott KR; Bache M
Cancer Gene Ther; 2007 Dec; 14(12):994-1001. PubMed ID: 17885676
[TBL] [Abstract][Full Text] [Related]
17. Celecoxib and a novel COX-2 inhibitor ON09310 upregulate death receptor 5 expression via GADD153/CHOP.
He Q; Luo X; Jin W; Huang Y; Reddy MV; Reddy EP; Sheikh MS
Oncogene; 2008 Apr; 27(18):2656-60. PubMed ID: 17968315
[TBL] [Abstract][Full Text] [Related]
18. Altered gene expression profiles define pathways in colorectal cancer cell lines affected by celecoxib.
Fatima N; Yi M; Ajaz S; Stephens RM; Stauffer S; Greenwald P; Munroe DJ; Ali IU
Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3051-61. PubMed ID: 18957522
[TBL] [Abstract][Full Text] [Related]
19. Failure of apoptosis and activation on NFkappaB by celecoxib and aspirin in lung cancer cell lines.
Gradilone A; Silvestri I; Scarpa S; Morrone S; Gandini O; Pulcinelli FM; Gianni W; Frati L; Aglianò AM; Gazzaniga P
Oncol Rep; 2007 Apr; 17(4):823-8. PubMed ID: 17342322
[TBL] [Abstract][Full Text] [Related]
20. A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells.
Basu GD; Liang WS; Stephan DA; Wegener LT; Conley CR; Pockaj BA; Mukherjee P
Breast Cancer Res; 2006; 8(6):R69. PubMed ID: 17156488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
